# A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

NCT07304024

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Phase 1, Phase 2 |
| **Sponsor** | University of Colorado, Denver |
| **Enrollment** | 344 participants |

## Key Eligibility Criteria

### Inclusion (9)

- Male or female between 45 and 65 years old (middle aged) at the screening/enrollment visit (Visit 1).
- Written informed consent obtained from the subject and ability for the subject to comply with the requirements of the study.
- Documentation of no more than a mild high-frequency hearing sensitivity loss and normal middle-ear function will be obtained using standard audiometric equipment with measurements done by an audiologist; Specifically, testing will show:
- bilateral hearing thresholds \< 20 dB HL at audiometric frequencies from 250 Hz to 4000 Hz inclusively, with no air-bone gaps \> 10 dB.
- symmetrical hearing thresholds between the ears through 8000 Hz, defined as \<20 dB difference at any single audiometric frequency or \< 15 dB difference at 2 or more contiguous frequencies.

... and 4 more (see full listing online)

### Exclusion (29)

- Any subjects who do not fall under the criteria defined above.
- Any of the following conditions which are listed as contraindications or warnings for use of the clinical trial drug (from labeling):
- Known sensitivity to clemastine fumarate or other antihistamines of similar composition
- Pregnancy or nursing mother as determined objectively with a urine pregnancy test
- Lower respiratory tract disease including asthma, or breathing difficulties such as emphysema or chronic bronchitis

... and 24 more (see full listing online)

## Locations (1 total)

University of Colorado Anschutz Medical Center, Aurora, Colorado, United States